ROS1
GeneWikipedia
6
MENTIONS
4
EPISODES
4
PODCASTS
Search complete. 6 mentions across 4 episodes found for "ROS1".
Sep 12, 2026
Narjust FlorezGUEST
When you have a cancer that is induced by tobacco, you tend to have central tumors with only enough involvement.
Narjust FlorezGUEST
But ROS1 fusions, ALK fusions, the cancer is different, very trophic to the brain, very trophic to the bone.
Narjust FlorezGUEST
So a lot of the young patients present with brain metastasis.
Narjust FlorezGUEST
A lot of young patients present with a large burden of disease because they also have a large reserve, right? If you have a patient that has COPD for tobacco use, they get a small tumor, they have symptoms.
5 MINS LATER
Narjust FlorezGUEST
We don't talk about young lung cancer or not.
Narjust FlorezGUEST
So I think the numbers are going to keep going up.
Narjust FlorezGUEST
I have a 19-year-old with ROS1 disease.
Narjust FlorezGUEST
I have a 23-year-old with KRAS G12D.
Wade T. IamsHOST
So this is about three to 4% of our patients with non-small cell lung cancer.
Wade T. IamsHOST
And one of the most important things that I think about with met exon 14 skipping is the the epidemiology or patient population characteristics are a little different here than EGFR, ALK, ROS1.
Wade T. IamsHOST
In this case, patients are often older, and there's a little bit more of a mix of men and women, although I see men and women with EGFR, ALK, ROS1.
Wade T. IamsHOST
I think we can get led down the wrong path if we stick to those stereotypes too much.
Wade T. IamsHOST
But metaxon-4 routine skipping especially is known to occur in patients with even sometimes significant smoking history.
Mitchell S von ItzsteinGUEST
And I call them modest predictors when I compare them to other biomarkers we use to guide cancer treatment.
Mitchell S von ItzsteinGUEST
So for example, if I find an EGFR, an ALK, or a ROS1 alteration in a lung cancer patient, the response rate to the matched targeted treatment can be as high as ninety percent.
Mitchell S von ItzsteinGUEST
If I find PD-L1 expression of greater than fifty percent, which is our best standard immune therapy biomarker in lung cancer, then less than a half of those patients respond to immune therapy.
Mitchell S von ItzsteinGUEST
And also a small but real proportion of PD-L1 negative patients still do get durable benefit from an immunotherapy, so a negative test doesn't let me withhold the therapy either.
Young Kwang ChaeGUEST
In the past, there wasn't much other than EGFR ALK.
Young Kwang ChaeGUEST
In the meantime, from ROS-1, RET, MET, BRAF, to emerging rare NRG-1 fusion targets, numerous targets have been developed, and the speed of development has become incredibly fast.
Young Kwang ChaeGUEST
And with better medicine coming out, There are a lot of drugs that can increase the survival rate of immune cancer by 5 years, and those drugs continue to be more specific and actionable.
Young Kwang ChaeGUEST
Precision oncology is not the future, but it's here.